Lux Biosciences
Biotechnology ResearchUnited States2-10 Employees
Lux Biosciences, Inc. is a privately held Biotechnology company focused on the treatment of ophthalmic diseases. Its submission stage project LUVENIQ is the oral formulation of a next-generation calcineurin inhibitor (voclosporin) for which positive phase 3 data has recently been obtained for the treatment of sight threatening non-infectious uveitis. Lux Biosciences is collaborating with the team at Isotechnika Pharma who invented the molecule and develops it for other indications.